Intas & Accord Expand Global Pegfilgrastim Reach with UDENYCA Acquisition

Intas & Accord Expand Global Pegfilgrastim Reach with UDENYCA Acquisition
Express pharma
Published onExpress pharma
Publish Date8 August 2025
Reading time2 Min

Share on Social Links

Category

StockBeginner GuideAngel InvestingSME IPOEconomy MarketAIFInvestmentsMore

Intas Pharmaceuticals and its U.S. specialty arm, Accord BioPharma, have announced the successful acquisition of UDENYCA® (pegfilgrastim-cbqv) from Coherus BioSciences. This move strengthens their position as one of the world’s leading suppliers of pegfilgrastim biosimilars.


Key Highlights:

  • Biosimilar Expansion: UDENYCA, a pegfilgrastim biosimilar, helps reduce infection risk in cancer patients undergoing chemotherapy and improves survival after radiation exposure.

  • Multiple Formulations: Now available in three formats—autoinjector, on-body injector, and prefilled syringe—enhancing treatment convenience for patients. More than 1.4 million units have already been distributed, benefitting over 300,000 patients.

  • Smooth Transition: Employees from Coherus across sales, marketing, supply chain, and manufacturing have joined Accord, ensuring continuity and growth.

  • Global Leadership: Accord is already a leader in pegfilgrastim biosimilars in Europe and was the first to launch the autoinjector. The acquisition significantly boosts its U.S. and worldwide presence.

Management Commentary:

  • Binish Chudgar, Chairman & MD of Intas, said the deal cements the company’s global leadership in pegfilgrastim.

  • Chrys Kokino, U.S. President of Accord, called it a pivotal moment that strengthens their presence in the U.S. market.

  • Paul Tredwell, EVP of Accord EMENA, highlighted that offering UDENYCA in three formulations brings them closer to becoming the world’s leading pegfilgrastim supplier.

Tags

StockBeginner GuideAngel InvestingSME IPOEconomy MarketAIFInvestmentsMore

Stay Connected, Stay Informed –

Join Our

WhatsApp

Channel!

Don’t miss out on exclusive updates, market trends, and real-time investment opportunities. Be the first to know about the latest unlisted stocks, IPO announcements, and curated Fact Sheets, delivered straight to your WhatsApp.

Pre Ipo

Pre Ipo

Upcoming IPO

Upcoming IPO

Unicorn

Unicorn